Meridian Bioscience Stock

Meridian Bioscience EBITDA per Employee

The EBITDA per Employee of Meridian Bioscience (VIVO) as of Sep 11, 2026 is 114,545.45 USD. In the previous year, EBITDA per Employee was 154,280.30 USD — a change of -25.75% (lower).

EBITDA per Employee

114,545.45USD

YoY

-25.75%

Last updated:

EBITDA per Employee of Meridian Bioscience is 2026 114,545.45 USD. EBITDA per Employee of Meridian Bioscience was 2025 154,280.30 USD. It decreases by -25.75% lower compared to the previous year.

The Meridian Bioscience EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2015
85,000.00 USD
Jan 1, 2016
81,212.12 USD
Jan 1, 2017
67,878.79 USD
Jan 1, 2018
67,727.27 USD
Jan 1, 2019
58,939.39 USD
Jan 1, 2020
103,030.30 USD
Jan 1, 2021
154,280.30 USD
Jan 1, 2022
114,545.45 USD
The Meridian Bioscience EBITDA per Employee history
YEAREBITDA per EmployeeYoY
114,545.45USD-25.75%
154,280.30USD+49.74%
103,030.30USD+74.81%
58,939.39USD-12.98%
67,727.27USD-0.22%
67,878.79USD-16.42%
81,212.12USD-4.46%
85,000.00USD+7.06%
79,393.94USD
Access this data via the Eulerpool API

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

EBITDA per Employee of Meridian Bioscience is 114,545.45 USD in 2026.

EBITDA per Employee of Meridian Bioscience changed from 154,280.30 USD to 114,545.45 USD, representing a -25.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Meridian Bioscience historically and in real time.

Access this data via the Eulerpool API

Workforce — Meridian Bioscience

All Key Metrics — Meridian Bioscience